Kancera reports that the company has registered an international patent application (PCT/EP2011/066250) for a new class of compounds targeting the energy metabolism of cancer cells. This new class of synthetic molecules inhibits the target protein PFKFB3. Inhibition of this...
Read MoreKancera has in collaboration with scientists at the Karolinska Institute identified active compounds that effectively kill pancreatic cancer cells. Annually over 100 000 people are diagnosed with pancreatic cancer in Europe and the US. Ratio of survival, five years...
Read MoreJanuary 1 - June 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...
Read MoreKancera is announcing today that the company has raised SEK 7.6m before issue costs in a rights issue. The capital raised will be used to further develop the company's ROR technology to attack solid tumors.
Read MoreAt a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors that are hard to treat. Kancera has already reported...
Read MoreiNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development...
Read MoreJanuary 1 - March 31, 2011 This Interim Report covers the period January 1 - March 31, 2011. As Kancera was established on April 28, 2010, there are no historical comparison figures. All figures relate to the Kancera Group...
Read MoreThe Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011. Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer...
Read MoreIn line with Kancera's strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of...
Read MoreApril 28 – December 31, 2010This Full Year Report relates to Kancera’s first financial year, covering the period April 28 – December 31, 2010. There are thus no historical comparison figures. Kancera’s conditional acquisition of iNovacia AB took place...
Read More